Evidence map›Paper›PMID 38973949›Full record

ArticleTranslational lung cancer research2024

Peptidyl-prolyl isomerase F as a prognostic biomarker associated with immune infiltrates and mitophagy in lung adenocarcinoma.

Zitong Feng, Lin Yuan, Luyuan Ma, Wenhao Yu, Fayez Kheir, Lukas Käsmann, Wolfgang M Brueckl, Kai Jin, Dingxin Wang, Yi Shen and 2 more

Abstract read
In one paragraph

Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zitong FengDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.ORCID https://orcid.org/0000-0003-1797-6782
Lin YuanDepartment of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Laboratory Medicine, Jinan, China.ORCID https://orcid.org/0009-0004-9321-6755
Luyuan MaDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
Wenhao YuDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
Fayez KheirDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Lukas KäsmannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Wolfgang M BruecklDepartment of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany.
Kai JinDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
Dingxin WangDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
Yi ShenDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
Rongyang LiDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
Hui TianDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) is among the most prevalent malignancies worldwide, with unfavorable treatment outcomes. Peptidyl-prolyl isomerase F ( Methods: The expression of Results: Conclusions: The findings of this study indicate that the prognosis-related gene

Indexed as

immunelung adenocarcinoma (LUAD)mitophagyPeptidyl-prolyl isomerase F (PPIF)prognosis

Identifiers

PMID38973949
PMCPMC11225036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.